<DOC>
	<DOCNO>NCT01846663</DOCNO>
	<brief_summary>The purpose study evaluate safety Rifaximin placebo subject severe hepatic impairment Hepatic Encephalopathy .</brief_summary>
	<brief_title>Efficacy , Safety , And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Male nonpregnant , nonbreast feed female ≥ 18 year old In remission demonstrate overt HE Had ≥1 episode overt HE associate liver disease within last 6 month MELD score ≥ 19 Has close family member personal contact familiar subject 's HE , provide continue oversight subject willing available subject conduct trial HIV History tuberculosis infection Chronic respiratory insufficiency Current infection receive antibiotic Renal insufficiency require dialysis Active spontaneous bacterial peritonitis infection Intestinal obstruction inflammatory bowel disease Active malignancy within last 5 year Current GI bleed GI hemorrhage within past 3 month Anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatic Encephalopathy</keyword>
	<keyword>Liver Failure</keyword>
	<keyword>Hepatic Insufficiency</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>